

SB175_L.098

HOUSE COMMITTEE OF REFERENCE AMENDMENT

Committee on Health & Insurance.

SB21-175 be amended as follows:

- 1 Amend reengrossed bill, page 18, line 3, strike "AN INITIAL" and
2 substitute "A".
- 3 Page 18, line 11, strike "AN INITIAL" and substitute "A".
- 4 Page 19, after line 1 insert:

5 "(2) NOTWITHSTANDING ANY PROVISION OF THIS PART 13 TO THE
6 CONTRARY, A BRAND-NAME DRUG, BIOLOGICAL PRODUCT, OR BIOSIMILAR
7 PRODUCT IS NOT SUBJECT TO AN AFFORDABILITY REVIEW BY THE BOARD
8 WITHIN THE FIRST FIVE YEARS OF THE BRAND-NAME DRUG'S, BIOLOGICAL
9 PRODUCT'S, OR BIOSIMILAR PRODUCT'S COMMERCIAL AVAILABILITY."
- 10 Renumber succeeding subsections accordingly.
- 11 Page 22, line 11, strike "10-16-1306 (7)(b)" and substitute "10-16-1306
12 (8)(b)".
- 13 Page 33, line 17, strike "10-16-1306 (4)" and substitute "10-16-1306 (5)"
14 and strike "10-16-1306 (6);" and substitute "10-16-1306 (7);".

** ** ** ** **